MAHEALANI ROACH: Open Payments
NPI 1649730292 · POWHATAN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,735 in 83 payments from 21 companies in 2025. Trend: 2023 $1,731 · 2024 $1,504 · 2025 $1,735
Food & beverage: $1,735
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $266 |
| ABBVIE INC. | 15 | $259 |
| Amgen Inc. | 12 | $244 |
| PFIZER INC. | 10 | $161 |
| Eisai Inc. | 1 | $125 |
| Lilly USA, LLC | 8 | $121 |
| TMS NeuroHealth Centers Inc. | 1 | $97 |
| Novo Nordisk Inc | 4 | $72 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $47 |
Products named: REPATHA, QULIPTA, Leqembi, FARXIGA, OTEZLA, NURTEC ODT, MOUNJARO, TMS NeuroHealth Centers Inc..
Industry payments across VA — which companies pay providers there.
